Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M32,571Revenue (TTM) $M21,903Net Margin (%)1.5Altman Z-Score0.8
Enterprise Value $M72,659EPS (TTM) $0.1Operating Margin %9.8Piotroski F-Score3
P/E(ttm)519Beneish M-Score-2.3Pre-tax Margin (%)3.8Higher ROA y-yN
Price/Book1.110-y EBITDA Growth Rate %7.4Quick Ratio0.7Cash flow > EarningsY
Price/Sales1.45-y EBITDA Growth Rate %-3.1Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow6.8y-y EBITDA Growth Rate %-44.2ROA % (ttm)0.5Higher Current Ratio y-yN
Dividend Yield %4.4PEG--ROE % (ttm)0.2Less Shares Outstanding y-yN
Payout Ratio %1,943Shares Outstanding M1,015ROIC % (ttm)3.1Gross Margin Increase y-yN

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

TEVA is held by these investors:



TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    What Will Make Man Smarter? Apr 10 2017 
    Risk-Reward With Teva Pharmaceutical Mar 27 2017 
    23 Questions With the Founder of WayUndervalued.com Mar 26 2017 
    Valeant: It's Not a Game of Chess Part I Mar 16 2017 
    Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
    David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 
    Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
    Naltrexone Showing More Potential in Drug Addiction Treatment Market Feb 05 2017 
    John Paulson's Bargain Stock Jan 30 2017 
    Teva: Good Value, Questionable Management? Jan 02 2017 

    More From Other Websites
    3 Dividend Stocks That Retirees Should Avoid Apr 22 2017
    Teva's new asthma inhaler poses first competition for GSK's Advair Apr 20 2017
    Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone... Apr 20 2017
    Teva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of Neurology Apr 19 2017
    Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Valeant Pharmaceuticals Apr 19 2017
    The Billionaire And The Drug Price-Fixing Scandal Apr 18 2017
    U.S. FDA raises concerns over Teva's plant in China Apr 13 2017
    Neurocrine Avoids Suicide Warning In Teva-Rivaling Drug; Stock Pops Apr 12 2017
    Cenovus  Energy, DryShips Dip into Wednesday’s 52-Week Low Club Apr 12 2017
    Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over... Apr 12 2017
    Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside Apr 12 2017
    Why Neurocrine Biosciences Stock Is Soaring Higher Today Apr 12 2017
    What Will Make Man Smarter? Apr 10 2017
    Teva Pharmaceutical Said to Be Exploring Sale of Women's Health Unit Apr 07 2017
    Teva to Report First Quarter 2017 Financial Results on May 11, 2017 Apr 06 2017
    Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst Apr 05 2017
    History Comes Back to Haunt Teva Pharmaceutical Industries, Sending Shares Down 8% in March Apr 05 2017
    Why Teva stock isn’t moving on its major Huntington’s disease drug approval Apr 05 2017
    Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Neurocrine Biosciences Apr 05 2017
    An Israeli pharma firm has found a way to make drugs longer lasting and more effective Apr 05 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)